Neurilemmomas are benign tumors which originate from Schwann cells. They rarely occur in the trachea or bronchus. We encountered two cases of endobronchial neurilemmoma and in this context, reviewed 48 cases previously reported in Japan. Neurilemmomas can occur in all regions of the bronchial tree and they often progress into both intraluminal and extraluminal spaces. Incomplete resection results in a local recurrence, despite being rare. As for appropriate therapies, surgery, bronchofiberoptic removal and yttrium aluminum garnet (YAG) laser resection can be chosen depending on the patient's status. (Internal Medicine 42: 1215-1218, 2003 
Introduction
Neurilemmomas are benign tumors which originate from Schwann cells. It is conceivable that neurilemmomas rarely occur in the trachea or bronchus, even though the exact frequency is unknown (1) . For the treatment of tracheal or endobronchial neurilemmomas as a palliative therapy, removal by fiberoptic bronchoscopy forceps or intrabronchial resection with a laser has recently been reported to be useful (2) , but local recurrence is also reported due to inadequate eradication (2) (3) (4) . We encountered two cases of endobronchial neurilemmoma, and reviewed 48 cases of pulmonary neurilemmoma in Japan in order to clarify the characteristics of this disease and selection of the appropriate tre atment.
Case Report
Case1
A 76-year-old man was under observation after he had received a right upper lobectomy of a squamous cell carcinoma of the lung (T2N2M0, stage ILL) in 1998. In 1999, because of a recurrence of lung cancer being suspected in the chest CT, he was admitted to our hospital.
On admission, he had no symptoms and his physical examination was essentially unremarkable. We performed a bronchofiberscopy and confirmed the histologic evidence of recurrence of lung cancer in the right upper bronchus and, by chance at the same time we detected a small polyp-like lesion in the spur of the middle and lower bronchus. A bronchofiberscopic biopsy was conducted and the subsequent HE stain (Fig. 1) revealed that the lesion consisted of spindle cells proliferated with Antoni A formation. The SI00 immunoperoxidase stain was positive (Fig. 2) while the alpha-smooth muscle actin (a-SMA) stain was negative, leading to our diagnosis that the lesion was a neurilemmoma. He was still asymptomatic and the small lesion (2 to 3 mm of diameter) permitted us to remove it by a transbronchial biopsy alone. He died one year later due to the recurrence of the cancer.
Case2
An 86-year-old man underwent an operation for gastric cancer. After the operation, he developed pneumonia and was intubated. Bronchofiberscopy was performed in order to remove bronchial mucus by suction and we detected a small polyp-like lesion (2 to 3 mm of diameter) in the left B5 a/b by chance. The small lesion was located apart from the pneumonia. The histological finding of the small polyp-like lesion was indicative of neurilemmoma. The small lesion allowed us to remove it by biopsy alone. The patient died a few weeks later due to the pneumonia. section of the lesion sometimes may lead to local recurrences. Nevertheless, presumably due to its latent growth, many years may be required for onset of the recurrence (2) (3) (4) . In the present two cases, the lesion was so small and detected incidentally, implying that there was no urgent need for removal, but biopsy was necessary as a diagnostic procedure. Transbronchial biopsy contributed to an apparent removal of the lesions. In conclusion, the diagnosis and selection of therapy are very complicated.
In some cases with central lesions and peripheral lesions, diagnosis by biopsy is sometimes difficult due to the inappropriate amount of specimens collected, finally requiring a surgical diagnosis. In emergent cases presenting with tracheal obstruction, surgery must be chosen. The most challenging situation is provided by an asymptomatic endobronchial lesion which is definitively diagnosed as a neurilemmoma. Surgery is indispensable to resect the lesion completely.
In the meantime, a bronchofiberoptic removal or an yttrium aluminum garnet (YAG) laser can be chosen as a palliative therapy; however, there is a possibility of local recurrence over a long interval. As a consequence, it is conceivable that bronchofiberoptic removal or a laser should be applied to younger patients as the first line therapy and if a local recurrence occurs, surgery should be chosen. For aged patients or patients with severe underlying diseases or malignancies, a bronchofiberoptic removal should be employed. To our knowledge, a local recurrence accompanied with malignant changes has not yet been reported, indicating that concerns about such a recurrence can be circumvented.
